SCIENTIFIC REPORTS

OPEN

Genetic diversity and antimicrobial susceptibility of *Nocardia* species among patients with nocardiosis

Received: 30 July 2015
Accepted: 05 November 2015
Published: 07 December 2015

Abodolrazagh Hashemi-Shahraki¹, Parvin Heidarieh², Saeed Zaker Bostanabad³, Mohamad Hashemzadeh⁴, Mohamad Mehdi Feizabadi⁵, Dean Schraufnagel⁶ & Mehdi Mirsaeidi⁷

The aim of this multicenter study was to determine the genetic diversity and antibiotic susceptibility of clinically isolated *Nocardia* species. One hundred twenty-seven patients with nocardiosis were randomly selected from 5 provinces of Iran. Molecular diagnosis of *Nocardia* species was performed using multilocus sequence analysis of gyrase B of the β subunit of DNA topoisomerase (*gyrB*), and 16S rRNA and subunit A of SecA preproteintranslocase (*secA1*). Antimicrobial susceptibility testing was performed following the Clinical and Laboratory Standards Institute recommendations. Thirty-five *N. cyriacigeorgica*, 30 *N. asteroides*, 26 *N. farcinica*, 12 *N. otitidiscaviarum*, and 10 *N. abscessus* cultures were studied. All isolates were susceptible to linezolid. All isolates of *N. cyriacigeorgica*, *N. asteroides*, *N. abscessus*, and *N. otitidiscaviarum* were susceptible to trimethoprim-sulfamethoxazole, while 8% of *N. farcinica* isolates were resistant to this drug. All *N. otitidiscaviarum* isolates were highly resistant to imipenem, but *N. cyriacigeorgica*, *N. asteroides*, *N. farcinica*, and *N. abscessus* were only moderate resistant. The susceptibility patterns vary with different species of *Nocardia*. Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing shows resistance. Linezolid also covers *Nocardia* well and could be a second line agent.

Nocardia can be found worldwide as a saprophytic pathogen in water, soil, decaying fecal deposits from animals and other ecological niches^{1,2}. Only a small proportion of the currently described *Nocardia* species are known to be human pathogens that affect both immunosuppressed and immunocompetent patients³. Nocardial infections range from minor cutaneous lesions to severe pulmonary or central nervous system disease^{1–3}. The incidence rates of *Nocardia* species isolation from clinical samples have been increasing worldwide in the recent decades^{3–5}. The reason for this increase could be related to advances in culturing and improved molecular methods as well as progress in oncology, rheumatology, and transplant medicine^{3,4,6,7}. Drug susceptibility testing of *Nocardia* isolates is recommended as a guide to therapy for cases of severe or disseminated infection, refractory cases, and those who are intolerant to treatment with sulfonamides^{1,4}. However, there is limited information about the distribution of the different *Nocardia* species and drug susceptibility of *Nocardia* worldwide including the Middle East. The aim of this study was to determine genetic diversity and drug susceptibility of clinical isolates of *Nocardia* from Iran.

¹Department of Epidemiology, Pasture Institute of Iran, Tehran, Iran. ²Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Alborz, Iran. ³Biology and Microbiology Department, Islamic Azad University, Parand Branch, Tehran, Iran. ⁴Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁵Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ⁶Division of Pulmonary and Critical Care, University of Illinois at Chicago, Chicago, IL, USA. ⁷Division of Pulmonary and Critical Care, University of Miami, Miami, FL, USA. Correspondence and requests for materials should be addressed to M.M. (email: msm249@med.miami.edu)

Figure 1. Geographic distribution of clinical isolates of *Nocardia* collected in the study. The figure was generated by AutoCAD MAP 3D“Autodesk® AutoCAD® Map 3D (<http://www.autodesk.co.uk/products/autocad-map-3d/overview>)” and then finalized by Photoshop CS5 software.

Material and methods

Organisms. One hundred twenty-seven clinical isolates of *Nocardia* from different major cities of Iran were studied between 2009 and 2015; 22 were from Khosestan (southwest Iran), 47 from Tehran (central Iran), 21 from Isfahan (central Iran), 13 from Mazandaran (northwestern Iran), and 10 from Kermanshah (northeast Iran)(Fig. 1). This study approved by Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (AJUMS), Ahvaz, Iran. Demographic, clinical, and microbiologic data were collected from patients’ medical records who signed the informed written consent. Isolates were sent to the Infectious and Tropical Diseases Research Center (AJUMS) for identification and subsequently antimicrobial susceptibility determination. All experimental protocols including sample collection and laboratory methods were approved by scientific committee of Health Research Institute (AJUMS).

A portion of the isolates (32specimens)were identified at the species level by multilocus sequence analysis (MLSA) of 16S rRNA, gyrase B of the β subunit of DNA topoisomerase (*gyrB*) and subunit A of SecA preprotein translocase (*secA1*) as previously described by McTaggart and colleagues⁸ to find out the reliability of each marker for identification. The remaining isolates were identified to species level by 16S rRNA analysis because of its acceptable discriminatory power. The 16S rRNA gene was amplified using 27F primer (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1525R (5′-AAGGAGGTGWTCCARCC-3′) and then was sequenced. The sequences were aligned and trimmed in BioNumerics (version 6.0.1) software (Applied Maths, Austin, TX) and were identified to species level. A representative 16S rRNA gene sequence from each of species was deposited in Genbank with KT003507-KT003513 accession numbers.

Broth microdilution testing. The drugs amikacin, amoxicillin-clavulanate, cefepime, cefotaxime, ceftriaxone, ciprofloxacin, clarithromycin, doxycycline, gentamicin, imipenem, linezolid, minocycline, moxifloxacin, tobramycin, trimethoprim-sulfamethoxazole (TMP-SMZ), and vancomycin were selected by testing based on National Committee for Clinical Laboratory Standards (NCCLS) recommendations⁹. Microtiter plates were prepared in-house, using standard twofold dilution of all antimicrobials except ampicillin and amoxicillin-clavulanate in cation-adjusted Mueller-Hinton broth. The plates were stored at -70°C and were thawed at room temperature immediately before use. The appropriate dilution of amoxicillin-clavulanate was freshly prepared immediately before use, then aliquoted, and placed in designated microtiter wells. Ten microliters of an inoculum with a turbidity equivalent to that of a 0.5 to 1.0 McFarland standard was dispensed into each well to give a final concentration of 10^4 to 10^5 CFU/mL⁹. The microtiter plates were incubated aerobically at 35°C and were read after 3 days. Growth was examined daily by visual inspection. The minimum inhibitory concentration (MIC) was defined as the lowest concentration of the drug that inhibited visible growth. MICs at which 50% (MIC_{50s}) and 90% (MIC_{90s})

	Pulmonary nocardiosis N(%)	Extrapulmonary nocardiosis N(%)	P-value
Age (mean $\pm$ SD)	55.8 $\pm$ 20	38.6 $\pm$ 19	<0.0001
Sex			0.760
Female	35(53)	34(56)	
Male	31(47)	27(44)	
Underlying condition			
Healthy	28(42)	28(46)	0.693
HIV*	7(11)	6(10)	0.886
Solid organ transplant	6(9)	5(8)	0.858
Diabetes	3(5)	4(7)	0.620
COPD**	6(9)	5(8)	0.858
Corticosteroid therapy	1(2)	8(13)	0.011
Others	15(22)	5(8)	N/A
Chest radiograph			N/A
Nodular or consolidative opacities	37(56)	N/A	
Cavitary lesion	18(30)	N/A	
Pleural effusion	8(14)	N/A	

Table 1. Shows the demographic information of study population. HIV: The human immunodeficiency virus, **COPD: chronic obstructive pulmonary disease, N/A: not applicable.

of isolates are inhibited were determined⁹. MIC50% and MIC90% were selected to provide an interpretation of the clinical significance of concentrations of an antimicrobial that inhibit the growth of an organism or kill it in laboratory systems (*in vitro*)^{10,11} and for defining the starting point for larger preclinical evaluations of novel antimicrobial agents¹². For TMP-SMZ, the MIC was the 80% inhibition endpoint of growth compared to the control. Susceptible and resistant breakpoints were defined according to the NCCLS recommendations⁹. Quality control of the MICs was performed by the testing of NCCLS recommended reference strains, including *Enterococcus faecalis* ATCC 29212, *Nocardia abscessus* DSM 44432, *Pseudomonas aeruginosa* ATCC 27853, and *Staphylococcus aureus* ATCC 29213. The control strains were obtained from Iranian Biological Resource Center (IBRC), Tehran, Iran.

Results

Out of 127 patients with nocardiosis 69 (54%) were females. The mean age was 47.6 (SD = 21) years. Table 1 shows the demographic information of study population. Almost half of the patients had at least one significant underlying condition, such as solid organ transplantation (11 patients, 8.7%), solid or hematologic malignancy (10 patients, 8%), HIV (13 patients, 10%), and receiving corticosteroids for rheumatologic disorders (9 patients, 7%). No known immunodeficiency was found in 56 (44%) patients. The most common symptoms were fever (52%) and cough (47%) in patients with pulmonary disease. Cavitary lesion was found on chest radiography in 18 (30%) persons with pulmonary disease. Pleural effusions occurred in 8 (14%). Lungs were the primary organ involved in 64 (50%) patients. Extrapulmonary nocardiosis included skin and soft tissue (31 persons, 24%) and central nervous system disease (brain abscess) (12 persons, 9%), and disseminated disease (18 persons, 14%). Bronchoalveolar fluid was the most common source of *Nocardia* isolation (60%). Extrapulmonary nocardiosis occurred more often in younger individuals (mean age 38.6 versus 55.8 in pulmonary group, $p < 0.0001$) and those who were taking corticosteroids for rheumatologic disorders (8, 13% vs. 1, 2% in pulmonary group, $p = 0.011$). Out of 127 clinical isolates, 31 (24%) were *N. asteroides*, 25 (20%) were *N. cyriacigeorgica*, 26 (21%) were *N. farcinica*, 12 (9%) were *N. otitidis*, 19 (15%) were *N. abscessus*, 6 (5%) were *N. wallacei*, 3 (2%) were *N. carnea*, 2 (2%) were *N. nova*, and one each were from *N. kruczkae*, *N. veterana*, and *N. arthritidis*. Some of these data were published elsewhere¹³.

Figure 2 shows that all clinical isolates of *Nocardia* were clearly differentiated and formed distinct branches in phylogenetic tree based on 16S rRNA. Table 2 shows that the *Nocardia* species most commonly isolated from human infections were *N. asteroides*, *N. farcinica* genotype I, and *N. cyriacigeorgica* genotype I. Isolates N 6, N 7, N 35, N 48, N 49, N 50, N 66 and N 67 were identified *N. asteroides* genotype II; N 9, N 10, N 21 and N 32 were grouped as *N. asteroides* genotype III, while N 18, N 19, N 20, N 61, N 62, N 71, N 78 were clustered as *N. asteroides* genotype I.

Figure 2. 16S rRNA sequence-based phylogenetic tree of clinical isolates of *Nocardia* with those of closely related species which computed by the NJ analyses and K2P model. The support of each branch, as determined from 1000 bootstrap samples, is indicated by percentages at each node. Bar 0.005 substitutions per nucleotide position.

	Pulmonary nocardiosis	Extrapulmonary nocardiosis
Most common isolated species	<i>N. asteroides</i>	<i>N. cyriacigeorgica</i>
Commonly isolated species	<i>N. farcinica</i>	<i>N. abscessus</i>
	<i>N. cyriacigeorgica</i>	<i>N. farcinica</i>
	<i>N. otitidiscaviarum</i>	<i>N. asteroides</i>
Frequently isolated species	<i>N. abscessus</i>	<i>N. wallacei</i>
		<i>N. otitidiscaviarum</i>
Rarely isolated species	<i>N. nova</i>	<i>N. nova</i>
	<i>N. wallacei</i>	<i>N. carnea</i>
	<i>N. arthritidis</i>	
	<i>N. carnea</i>	
	<i>N. veterana</i>	
	<i>N. kruczakiae</i>	

Table 2. *Nocardia* species isolated from human infection in Iran. Commonly isolated was defined as frequency rate >10%, frequently isolated was defined as frequency rate between 10% and 3%, rarely isolated was defined as frequency <3%.

Drug susceptibility testing. Table 3 presents the MICs at which 50% (MIC₅₀s) and 90% (MIC₉₀s) of isolates are inhibited and the range of MICs for all *Nocardia* isolates. All *Nocardia* isolates were resistant to vancomycin.

N. asteroides. Among the 31 isolates of *N. asteroides*, all were susceptible to TMP-SMZ and linezolid. Amoxicillin-clavulanic acid, cefepime, ceftriaxone, ciprofloxacin, imipenem, moxifloxacin, and tobramycin had moderate activity, while clarithromycin had poor activity against the clinical isolates of *N. asteroides*. The MIC₉₀ for both linezolid and TMP-SMZ was 1 (μg/ml), but, for ceftriaxone this value was 128 (μg/ml).

N. farcinica. All 26 isolates of *N. farcinica* were susceptible to amikacin and linezolid, and all were resistant to ceftriaxone, doxycycline, gentamicin, minocycline, and tobramycin. Two (8%) of 26 isolates were resistant to TMP-SMZ. For amikacin and linezolid the lowest concentration of MIC₉₀ (1 μg/ml)

Species (number of isolates)/antibiotics	MIC (µg/ml)		Number (%) of isolates		
	50%	90%	Susceptible	Intermediate	Resistant
<i>N. cyriacigeorgica</i> (25)					
Amikacin	0.125	1	25(100)	—	0 (0)
Amoxicillin-clavulanic acid	8	64	0(0)	5(20)	20(80)
Ceftriaxone	4	64	20(80)	2(8)	3(12)
Ciprofloxacin ^a	4	32	0(0)	7(28)	18(72)
Clarithromycin ^b	2	8	8(32)	7(28)	10(40)
Cefepime	0.125	0.5	25(100)	0(0)	0(0)
Cefotaxime	4	64	20(80)	1(4)	4(16)
Gentamicin	1	2	25(100)	0(0)	0(0)
Doxycycline	0.25	16	18(72)	3(12)	4(16)
Imipenem	1	64	15(60)	2(8)	8(32)
Linezolid ^c	0.125	0.5	25(100)	—	—
Minocycline	8	32	0(0)	3(8)	22(88)
Moxifloxacin	32	64	0(0)	0(0)	25(100)
Tobramycin	0.125	0.5	25(100)	0(0)	0(0)
TMP-SMZ	0.125	0.5	25(100)	—	0(0)
<i>N. asteroides</i>(31)					
Amikacin	2	16	24(77)	—	7 (23)
Amoxicillin-clavulanic acid	16	32	17(55)	3(10)	11(35)
Ceftriaxone	4	128	17(55)	3(10)	11(35)
Ciprofloxacin ^a	0.125	8	17(55)	5(16)	9(29)
Clarithromycin ^b	16	32	2(6)	3(10)	26(84)
Cefepime	16	64	12(39)	5(16)	14(45)
Cefotaxime	32	64	10(32)	9 (29)	12(39)
Gentamicin	0.125	4	28(90)	0(0)	3(10)
Doxycycline	0.125	32	16(52)	7(23)	8(25)
Imipenem	1	32	28(90)	0(0)	3(10)
Linezolid ^c	0.125	1	31(100)	—	—
Minocycline	8	32	8(25)	10(32)	13(43)
Moxifloxacin	8	16	12 (39)	8(25)	11(35)
Tobramycin	4	16	19(61)	5(16)	7(23)
TMP-SMZ	0.5	1	31(100)	—	0 (0)
<i>N. farcinica</i> (26)					
Amikacin	0.125	1	26(100)	—	0 (0)
Amoxicillin-clavulanic acid	2	32	16 (61)	2(8)	8(31)
Ceftriaxone	128	256	0 (0)	0(0)	26(100)
Ciprofloxacin ^a	0.125	2	10(38)	5(20)	11(42)
Clarithromycin ^b	8	32	0(0)	4(15)	22(85)
Cefepime	32	64	0(0)	4(15)	22(85)
Cefotaxime	32	64	0(0)	0(0)	26(100)
Gentamicin	32	128	0(0)	0(0)	26(100)
Doxycycline	16	32	0(0)	0(0)	26(100)
Imipenem	1	32	15(58)	3(11)	8 (31)
Linezolid ^c	0.125	1	26(100)	—	—
Minocycline	8	32	0(0)	0(0)	26(100)
Moxifloxacin	4	16	10(38)	3(11)	13(51)
Tobramycin	16	32	0(0)	0(0)	26(100)
Continued					

Species (number of isolates)/antibiotics	MIC ($\mu\text{g/ml}$)		Number (%) of isolates		
	50%	90%	Susceptible	Intermediate	Resistant
TMP-SMZ	0.5	8	24(92)	—	2(8)
<i>N. otitidiscaviarum</i> (12)					
Amikacin	0.125	2	12(100)	—	0(0)
Amoxicillin-clavulanic acid	32	64	0(0)	0(0)	12(100)
Ceftriaxone	64	256	0(0)	2(17)	10(83)
Ciprofloxacin ^a	4	8	2(16)	3(25)	7(58)
Clarithromycin ^b	4	16	4(33)	1(8)	7(58)
Cefepime	16	32	4(33)	4(33)	4(33)
Cefotaxime	64	128 ^c	2(17)	1(8)	9(75)
Gentamicin	2	32	6(50)	0(0)	6(50)
Doxycycline	8	32	1(8)	1(8)	10(83)
Imipenem	16	64	0(0)	0(0)	12(100)
Linezolid ^c	0.125	1	12(100)	—	—
Minocycline	8	32	1(8)	1(8)	10(83)
Moxifloxacin	4	16	3(25)	3(25)	6(50)
Tobramycin	0.5	1	12(100)	0(0)	0(0)
TMP-SMZ	0.125	0.5	12(100)	—	0(0)
<i>N. abscessus</i> (19)					
Amikacin	16	32	7(37)	—	12(63)
Amoxicillin-clavulanic acid	4	64	8(42)	2(11)	9(47)
Ceftriaxone	0.5	1	19 (100)	0(0)	0(0)
Ciprofloxacin ^a	4	16	0(0)	0(0)	19(100)
Clarithromycin ^b	4	16	6(31)	3(16)	10(53)
Cefepime	8	32	10(53)	3(16)	6(31)
Cefotaxime	8	64	10 (53)	3(16)	6(31)
Gentamicin	0.5	1	19(100)	0(0)	0(0)
Doxycycline	1	8	4(21)	3(16)	12(63)
Imipenem	8	32	4(21)	2(11)	13(68)
Linezolid ^c	0.125	1	19(100)	—	—
Minocycline	4	16	5(26)	2(11)	12(63)
Moxifloxacin	4	16	0(0)	0(0)	19(100)
Tobramycin	0.5	1	19(100)	0(0)	0(0)
TMP-SMZ	0.125	0.5	19(100)	—	0(0)

Table 3. Drug susceptibility testing results for clinical isolates of *Nocardia*. ^aCiprofloxacin may be used as a class representative for the older fluoroquinolones: ciprofloxacin, ofloxacin, and levofloxacin.

^bClass representative for newer macrolides. ^cProposed breakpoint with linezolid MIC values $>8\mu\text{g/mL}$ for *Nocardia* isolates have been adapted from reference³⁷. Breakpoints are arbitrary since there are currently no NCCLS interpretive criteria.

was detected. Ceftriaxone had the highest concentration of MIC90 value between all tested antibiotics (256 $\mu\text{g/ml}$).

***N. cyriacigeorgica*.** The 25 *N. cyriacigeorgica* clinical isolates were susceptible to amikacin, cefepime, gentamicin, linezolid, tobramycin, and TMP-SMZ. *N. cyriacigeorgica* generally had good sensitivity to cefotaxime, ceftriaxone, clarithromycin, doxycycline, imipenem, and minocycline, but poor sensitivity to amoxicillin-clavulanic acid, ciprofloxacin, and minocycline. All isolates were resistant to moxifloxacin. The MIC90 for cefepime, linezolid, tobramycin and TMP-SMZ was 0.5 $\mu\text{g/ml}$ and for amoxicillin-clavulanic acid, ceftriaxone, cefotaxime, imipenem and moxifloxacin was 64 ($\mu\text{g/ml}$).

***N. abscessus*.** All 19 isolates of *N. abscessus* were susceptible to ceftriaxone, gentamicin, linezolid, tobramycin, and TMP-SMZ. Cefepime, cefotaxime, doxycycline, imipenem, and minocycline showed good activity against *N. abscessus* isolates. Amikacin, amoxicillin-clavulanic acid, and clarithromycin had low activity against the clinical isolates of *N. abscessus*, and ciprofloxacin, moxifloxacin had no activity against these isolates. Ceftriaxone, gentamicin, linezolid and tobramycin had MIC₉₀ (1 µg/ml). The MIC₉₀ for amoxicillin-clavulanic acid and cefotaxime was 64 µg/ml and for amikacin, cefepime and imipenem was 32 µg/ml.

***N. otitidiscaviarum*.** All 12 isolates of *N. otitidiscaviarum* were susceptible to amikacin, linezolid, tobramycin, and TMP-SMZ, whereas there was poor activity to ceftriaxone, doxycycline, and minocycline, and all isolates were resistant to amoxicillin-clavulanic acid, imipenem. The MIC₉₀ for amikacin, linezolid and TMP-SMZ was 0.125 µg/ml.

***N. wallacei*.** All 6 isolates were resistance to amikacin, clarithromycin, imipenem, moxifloxacin were susceptible to ceftriaxone, cefepime, cefotaxime, gentamicin, linezolid, tobramycin and TMP-SMZ. Amoxicillin-clavulanic acid, doxycycline and minocycline demonstrated poor activity against the isolates.

***N. carnea*.** All 3 isolates of *N. carnea* were resistance to amikacin, amoxicillin-clavulanic acid, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, moxifloxacin were susceptible to cefepime, cefotaxime, gentamicin, linezolid, tobramycin and TMP-SMZ. Poor activity was recorded for doxycycline and minocycline.

One isolate from each species of *N. arthritidis*, *N. kruczakiae*, *N. nova* and *N. veteran* were studied for drug susceptibility tests. All of them were susceptible to amikacin, amoxicillin-clavulanic acid, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, tobramycin and TMP-SMZ.

Discussion

N. asteroides was the most frequently recovered species in our study. It was followed by *N. farcinica* and *N. cyriacigeorgica*. This pattern was different between individuals with pulmonary and extrapulmonary nocardiosis, with *N. cyriacigeorgica* being the most common in extrapulmonary disease. Our study found that extrapulmonary nocardiosis occurs more commonly in younger persons (mean age 38) compared to pulmonary nocardiosis (mean age 56) and in those with rheumatologic disorders taking corticosteroids.

Although cases reports have shown *N. cyriacigeorgica*¹⁴, *N. asteroides* complex¹⁵ and *N. nova* complex¹⁶ in Iran, but to our knowledge, there is no report of drug susceptibility on clinical isolates of *Nocardia* from Iran as well as the Middle Eastern countries.

The lungs are the most common organ that *Nocardia* infects (up to 70%), with *N. asteroides* complex the species most often isolated from this site¹⁷. Yamagata and colleagues reported that patients with rheumatologic disorders who took corticosteroid were at higher risk of extrapulmonary nocardiosis⁶. Our study confirmed the higher incidence extrapulmonary nocardiosis in those taking corticosteroids before the *Nocardia* infection. This information may serve as a warning to clinicians about the risk of corticosteroids and disseminated nocardial infection.

Nocardia species cause a wide variety of diseases and have variable drug susceptibility profiles. Since the 1940s, the sulfonamides have been the treatment of choice for nocardiosis^{1,18}. Later, the combination of trimethoprim with sulfamethoxazole became the most commonly recommended treatment for these infections¹. Other therapies including amikacin, a combination of amikacin and a beta-lactam such as ceftriaxone or imipenem, and a combination with linezolid have also been suggested for therapy of patients with serious disease^{1,19}.

Susceptibility testing of *Nocardia* isolates to the antibiotics showed that *N. cyriacigeorgica* isolates were generally sensitive to our selected antibiotics. All were susceptible to amikacin, cefepime, gentamicin, linezolid, tobramycin, and TMP-SMZ; and the majority was somewhat less susceptible to cefotaxime, ceftriaxone, doxycycline, imipenem, and minocycline. These findings are consistent with those reported by Glupczynski and colleagues²⁰. Further, Larruskain and colleagues noted that *N. cyriacigeorgica* isolates from Spain were susceptible to amikacin, gentamicin, linezolid, tobramycin, and TMP-SMZ²¹.

Schlager and colleagues from the United States reported that *N. cyriacigeorgica* isolates were susceptible to amikacin, linezolid, tobramycin, and TMP-SMZ, and were resistant to amoxicillin-clavulanic acid, ciprofloxacin, clarithromycin, minocycline, and moxifloxacin²². However, our isolates were highly resistant only to amoxicillin-clavulanic acid, ciprofloxacin, and moxifloxacin. Ceftriaxone, imipenem, linezolid, and TMP-SMZ were reported as the most effective antimicrobial agents against *N. cyriacigeorgica* isolates in Taiwan²³, which agrees with our results.

Among the 31 isolates of *N. asteroides*, linezolid and TMP-SMZ were active against all isolates while moderate susceptibility was detected for imipenem, amoxicillin-clavulanic acid, cefepime, ceftriaxone, ciprofloxacin, moxifloxacin, and tobramycin. Clarithromycin had poor activity against clinical isolates of *N. asteroides* in our study. In the preliminary evaluation of antimicrobial agents against *N. asteroides* isolates in 1984, the beta-lactams including third-generation cephalosporins were generally reported ineffective, whereas minocycline, doxycycline, and sulfamethoxazole were recommended for therapy²⁴. Four years later, Wallace and colleagues showed that the most active parenteral agents against *N. asteroides* were amikacin, cefotaxime, ceftriaxone, imipenem, minocycline, and sulfonamides²⁵. Although Schlager

and colleagues found that all *N. asteroides* isolates were susceptible to amikacin, imipenem, linezolid, tobramycin, and TMP-SMZ²², we found less susceptibility among *N. asteroides* isolates in our study.

N. farcinica is more likely to have multidrug resistance and high level resistance to imipenem, ceftriaxone, clarithromycin, tobramycin, and moxifloxacin^{21,22}. Although TMP-SMZ has been the drug of choice for the treatment of nocardiosis^{7,18,24,25}, we found 8% (2 isolates) of *N. farcinica* were TMP-SMZ resistant. Larruskain and colleagues in Spain found 16.1%²¹, Uhde and colleagues found 42%²⁶ from the United States, and Tremblay and colleagues also reported 42% TMP-SMZ resistant strains from Canada²⁷. Another study from Spain, reported that 9 of 19 *N. farcinica* isolates (47%) were TMP-SMZ resistant⁷. Furthermore, Lai and colleagues from Taiwan reported a low incidence (9%) similar to ours²³, and another report from the United States also found only 2% TMP-SMZ resistance²⁸ and sulfonamide and TMP-SMZ resistance was not seen in South Africa²⁹. The similarity between the 2 North American countries and divergence in Europe and Iran suggests there may be geographical differences in *N. farcinica* drug sensitivity with unknown reasons. We speculate that the difference in drug susceptibility to TMP-SMZ could be related to differences in laboratory methodology and interpretation criteria. More recently, Valdezate and colleagues reported association of high-level sulfonamide resistance and the presence of plasmid-borne integrons carrying *sul* genes (*sul1* and *sul2*) in SXT-resistant *Nocardia* strains³⁰. These type of integrons, and the corresponding plasmids, are commonly detected in bacteria living in different ecological niches³¹.

In our study, resistance to β -Lactams antibiotics were detected among the isolates, which might be related to a mutational change affecting the inhibitor and active site (s) in the beta-lactamase³².

Our *Nocardia* isolates showed moderate resistance to quinolones. Valdezate and colleagues³⁰ could not find plasmid-mediated quinolone resistance genes (*qnrA*, *qnrB*, *qnrC*, and *qnr*) or the gene for the aminoglycoside acetyltransferase for modify ciprofloxacin³³ or efflux pump *qepA*³⁴ and or nucleotide changes observed in *gyrA*³⁵. Further, study considering the resistance mechanisms and how antibiotic resistance spreading among *Nocardia* strains are required.

All *N. otitidiscaviarum* species were susceptible to TMP-SMZ. Our data was in agreement with those reported by others^{22,23}. In contrast with our data, moderate resistance to TMP-SMZ (32%) among *N. otitidiscaviarum* was reported by Uhde and colleagues²⁶.

N. abscessus were susceptible to ceftriaxone, gentamicin, linezolid, tobramycin, and TMP-SMZ in our study. The same susceptibility profile of *N. abscessus* was reported before^{21,22}.

Linezolid, a relatively new class of antibiotics, showed extraordinary *in vitro* activity against all of the major clinically significant species of *Nocardia*^{19,36}. Our findings are in agreement with reports from different parts of world that clearly demonstrate that linezolid is an effective alternative for the treatment of nocardiosis.

In conclusion, *N. asteroides* was the most common species isolated from pulmonary nocardiosis and *N. cyriacigeorgica* was the most frequently recovered species from extrapulmonary nocardial infections. Clinical isolates of *Nocardia* species in our study had varied drug susceptibility patterns, which were similar to what have been reported from other geographic area, with some exceptions. Importantly, TMP-SMZ resistance was low in the current study. Based on this information, we feel confident recommending TMP-SMZ as the first choice for the treatment of nocardiosis in Iran. Linezolid broadly covers *Nocardia* and would be a second choice, although the costs are considerably greater. We strongly recommend that drug sensitivity testing is helpful in all patients with serious disease.

References

1. Brown-Elliott, B. A., Brown, J. M., Conville, P. S. & Wallace, R. J. Clinical and laboratory features of the *Nocardia* spp. based on current molecular taxonomy. *Clin Microbiol Rev.* **19**, 259–282 (2006).
2. Brown, J., McNeil, M. & Desmond, E. *Nocardia*, *Rhodococcus*, *Gordona*, *Actinomadura*, *Streptomyces*, and other actinomycetes of medical importance in *Manual of Clinical Microbiology* (eds Jorgensen, J. H. et al.) 370–398 (American Society for Microbiology, 1995).
3. Minero, M. V. et al. Nocardiosis at the turn of the century. *Medicine*. **88**, 250–261 (2009).
4. Saubolle, M. A. & Sussland, D. Nocardiosis review of clinical and laboratory experience. *J Clin Microbiol.* **41**, 4497–4501 (2003).
5. Munoz, J. et al. Clinical and microbiological features of nocardiosis 1997–2003. *J Med Microbiol.* **56**, 545–550 (2007).
6. Yamagata, M., Hirose, K., Ikeda, K. & Nakajima, H. Clinical characteristics of *Nocardia* infection in patients with rheumatic diseases. *Clin Dev Immunol.* **2013**, 818654, doi: 10.1155/2013/818654 (2013).
7. Torres, O. et al. Infection caused by *Nocardia farcinica*: case report and review. *Eur J Clin Microbiol Infect Dis.* **19**, 205–212 (2000).
8. McTaggart, L., Richardson, S., Witkowska, M. & Zhang, S. Phylogeny and identification of *Nocardia* species on the basis of multilocus sequence analysis. *J Clin Microbiol.* **48**, 4525–4533 (2010).
9. Woods, G. L. et al. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes: approved standard. *NCCLS*, **23**, (2003).
10. Davison, H. C., Woolhouse, M. E. & Low, J. C. What is antibiotic resistance and how can we measure it? *Trends Microbiol* **8**, 554–559 (2000).
11. Prescott, J. & Baggot, J. In *Antimicrobial therapy in veterinary medicine* (eds Giguère, S. et al.) 229–251 (Iowa State University Press Ames, 1993).
12. O'Neill, A. J. & Chopra, I. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. *Expert Opin Investig Drugs.* **13**, 1045–1063 (2004).
13. Hashemi-Shahraki, A. et al. Species spectrum of *Nocardia* spp. isolated from suspected tuberculosis patients. *Health.* **7**, 847–858 (2015).
14. Shojaei, H. et al. Clinical isolation of *Nocardia cyriacigeorgica* from patients with various clinical manifestations, the first report from Iran. *Med Mycology J.* **52**, 39–43 (2011).

15. Eshraghi, S. S. *et al.* Isolation and identification of *Nocardia asteroides* complex isolated from thigh abscess in a patient with Behçet's syndrome: the first report from Iran. *T ehran Univ Med J.* **7**, 1476–749 (2013).
16. Fatahi Bafghi, M. *et al.* Isolation and phenotypic identification of *Nocardia nova* complex of breast abscess in a patient with pemphigus vulgaris: the first report from Iran. *Iran J Breast Dis.* **5**, 44–49 (2012).
17. Das, A. K., Nandy, S., Dudeja, M., Tiwari, R. & Alam, S. The incidence of nocardiosis at pulmonary and extra – pulmonary sites. *J Clin Diagn Res.* **7**, 1427–1429 (2013).
18. Benbow E., Jr, Smith, D. & Grimson, K. Sulfonamide therapy in actinomycosis: two cases caused by aerobic partially acid-fast actinomycetes. *Am Rev Tuberc.* **49**, 395–407 (1944).
19. Moylett, E. H. *et al.* Clinical experience with linezolid for the treatment of *Nocardia* infection. *Clin Infect Dis.* **36**, 313–318 (2003).
20. Glupczynski, Y., Berhin, C., Janssens, M. & Wauters, G. Determination of antimicrobial susceptibility patterns of *Nocardia* spp. from clinical specimens by Etest. *Clin Microbiol Infect.* **12**, 905–912 (2006).
21. Larruskain, J., Idigoras, P., Marimón, J. M. & Pérez-Trallero, E. Susceptibility study of 186 *Nocardia* spp. isolates to 20 antimicrobial agents. *Antimicrob Agents Chemother.* **55**, 2995–8 (2011).
22. Schlager, R., Fisher, M. A. & Hanson, K. E. Susceptibility profiles of *Nocardia* isolates based on current taxonomy. *Antimicrob Agents Chemother.* **58**, 795–800 (2014).
23. Lai, C.-C. *et al.* Multicenter study in Taiwan of the *in vitro* activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various *Nocardia* species. *Antimicrob Agents Chemother.* **55**, 2084–2091 (2011).
24. Dewsnup, D. H. & Wright, D. N. *In vitro* susceptibility of *Nocardia asteroides* to 25 antimicrobial agents. *Antimicrob Agents Chemother.* **25**, 165–167 (1984).
25. Wallace, R., Steele, L. C., Sumter, G. & Smith, J. M. Antimicrobial susceptibility patterns of *Nocardia asteroides*. *Antimicrob Agents Chemother.* **32**, 1776–1779 (1988).
26. Uhde, K. B. *et al.* Antimicrobial-resistant *Nocardia* isolates, United States, 1995–2004. *Clinical infectious diseases* **51**, 1445–1448 (2010).
27. Tremblay, J., Thibert, L., Alarie, I., Valiquette, L. & Pépin, J. Nocardiosis in Quebec, Canada, 1988–2008. *Clin Microbiol Infect.* **17**, 690–696 (2011).
28. Brown-Elliott, B. A. *et al.* Sulfonamide resistance in isolates of *Nocardia* spp. from a US multicenter survey. *Journal of clinical microbiology* **50**, 670–672 (2012).
29. Lowman, W. & Aithma, N. Antimicrobial susceptibility testing and profiling of *Nocardia* species and other aerobic actinomycetes from South Africa: comparative evaluation of broth microdilution versus the Etest. *J Clin Microbiol.* **48**, 4534–4540 (2010).
30. Valdezate, S. *et al.* Resistance gene pool to co-trimoxazole in non-susceptible *Nocardia* strains. *Front Microbiol.* **6**, 376 (2015).
31. Stalder, T., Barraud, O., Casellas, M., Dagot, C. & Ploy, M.-C. Integron involvement in environmental spread of antibiotic resistance. *Front Microbiol.* **3**, 119 (2012).
32. Steingrube, V. *et al.* Acquired resistance of *Nocardia brasiliensis* to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid. *Antimicrob Agents Chemother.* **35**, 524–528 (1991).
33. Park, C. H., Robicsek, A., Jacoby, G. A., Sahm, D. & Hooper, D. C. Prevalence in the United States of aac (6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother.* **50**, 3953–3955 (2006).
34. Kim, H. B. *et al.* Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. *Antimicrob Agents Chemother.* **53**, 639–645 (2009).
35. Maruri, F. *et al.* A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. *J Antimicrob Chemother.* **67**, 819–831 (2012).
36. Brown-Elliott, B. A. *et al.* *In Vitro* Activities of linezolid against multiple *Nocardia* species. *Antimicrob Agents Chemother.* **45**, 1295–1297 (2001).
37. Brown-Elliott, B. A., Ward, S. C., Crist, C. J., Mann, L. B., Wilson, R. W. & Wallace, R. J., Jr. *In vitro* activities of linezolid against multiple nocardia species. *Antimicrobial agents and chemotherapy* **45**, 1295–1297 (2001).

Acknowledgements

We appreciate the financial support of Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.

Author Contributions

Conception, hypotheses delineation, and design of the study: M.M., A.H.S. and P.H. The laboratory tests, data analysis and interpretation of such information: M.M., A.H.S., P.H., S.Z.B., M.H. and M.M.F. Writing the article or substantial involvement in its revision before submission: M.M., M.M.B., P.H. and D.S.

Additional Information

Competing financial interests Dr. Mehdi Mirsaeidi who is a Federal Employee at Miami VA Medical Center.

How to cite this article: Hashemi-Shahraki, A. *et al.* Genetic diversity and antimicrobial susceptibility of *Nocardia* species among patients with nocardiosis. *Sci. Rep.* **5**, 17862; doi: 10.1038/srep17862 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>